Novo Nordisk brings oral semaglutide to the UAE as first launch outside United States
Novo Nordisk has started distributing Wegovy pill (oral semaglutide) in the United Arab Emirates, marking the first market outside the United States to make the treatment available. The move extends the Danish company’s rollout of an oral formulation of a GLP-1 receptor agonist designed for long-term weight management, and arrives amid rising regional concern about obesity and cardiometabolic disease.
What the product is and the evidence behind it
Wegovy pill is an oral formulation of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Novo Nordisk says the approval in the UAE follows data generated in the OASIS 4 clinical programme, which reported about a 17% mean weight reduction in adults with obesity or overweight and at least one comorbidity when the 25 mg daily regimen was adhered to. The company also notes that roughly one in three participants achieved 20% or greater weight loss in the trial.
Regulatory authorities in the United States and the Emirates Drug Establishment have authorised the pill for weight management. According to Novo Nordisk, Wegovy pill is currently the only approved oral weight-loss therapy authorised by both the US Food and Drug Administration and the EDE that also carries an indication to reduce the risk of major adverse cardiovascular events, including heart attack and stroke, for adults with established cardiovascular disease and overweight or obesity.
Why the UAE was chosen and what it means for rollout strategy
In announcing the launch, Novo Nordisk said the UAE demonstrated readiness across several dimensions that shape its global rollout strategy: patient demand, healthcare professional preparedness, and the infrastructure to support long-term obesity management, including telehealth. The company has signalled further launches into select markets in the second half of 2026.
Making the pill available in the UAE first outside the US suggests Novo Nordisk views the market as receptive to newer obesity treatments and capable of integrating them into care pathways. The UAE has relatively high obesity prevalence compared with global averages; Novo Nordisk cited a figure of 28% of adults living with obesity in the country, and estimates that nearly 7.5 million people in the UAE will be living with obesity or overweight by 2035.
Clinical and system-level considerations for UAE healthcare
Clinicians and health systems in the UAE will need to consider how an oral GLP-1 product fits into existing obesity management protocols. The oral route may improve uptake among patients hesitant about injectable therapies, but adherence is critical: reported trial benefits are conditional on patients following the daily dosing regimen.
From a safety standpoint, Novo Nordisk reports the pill’s tolerability profile is consistent with previous semaglutide studies. Still, prescribers will need to weigh individual cardiovascular risk, comorbidities and potential side effects when initiating therapy. The cardiovascular risk reduction indication, limited to adults with established cardiovascular disease and excess weight, is likely to shape prescribing practices and reimbursement discussions.
Market and payer implications
Introducing a high-efficacy weight-loss pill into a market raises questions about access and cost. Novo Nordisk has not disclosed pricing for the UAE, and reimbursement approaches will probably vary across public and private payers. For payers, the cardiovascular event reduction claim in patients with established heart disease could be an important factor when considering coverage, given the potential downstream cost offsets from avoided heart attacks or strokes. Health systems may also need to expand capacity for long-term obesity follow-up, multidisciplinary care and monitoring to realise projected clinical benefits.
Broader industry context
The expansion of GLP-1 therapies into oral formats reflects a broader shift in how obesity is treated, moving away from lifestyle-only models toward a combination of pharmacotherapy, behavioural interventions and system-level support. For pharmaceutical companies, demonstrating real-world adherence and long-term outcomes will be essential to securing payer support and clinician confidence.
Outlook
The UAE launch positions the country as an early adopter for an oral GLP-1 weight-loss therapy outside the US. For Novo Nordisk, it is an initial step in a wider international rollout planned through 2026. For UAE healthcare providers and payers, the next phase will focus on integrating the medication into care pathways, establishing reimbursement terms and monitoring patient outcomes in routine practice.
About the company
Novo Nordisk, founded in 1923 and headquartered in Denmark, markets diabetes and obesity medicines globally and employs tens of thousands of staff across multiple countries. The company has framed the Wegovy pill launch as part of an effort to expand access to newer obesity treatments.
